Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Up 0.6 %

Shares of NASDAQ BCLI opened at $1.64 on Monday. The firm has a market cap of $9.35 million, a P/E ratio of -0.34 and a beta of 0.74. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89. The business’s 50 day moving average is $1.88 and its 200-day moving average is $2.27.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.